There are 2789 resources available
852P - Feasibility and safety of HiDAC in AML patients who have achieved CR with hypomethylating agents: Prospective study
Presenter: Sanjo Varghese
Session: ePoster Display
Resources:
Abstract
853P - PRAME expression and ImmTAC TCR bispecific sensitivity in acute myeloid leukaemia in the presence and absence of the hypomethylating agent decitabine
Presenter: Camille Britton-Rivet
Session: ePoster Display
854P - Final results of a phase II study of tipifarnib in chronic myelomonocytic leukemia (CMML) and other myelodysplastic/myeloproliferative neoplasms (MDS/MPN)
Presenter: Mrinal Patnaik
Session: ePoster Display
855P - Exploring the cardio-cerebrovascular outcomes and thromboembolic risks among BCR-ABL1-negative myeloproliferative neoplasms treated with ruxolitinib: Systematic review and meta-analysis
Presenter: Boby Pratama Putra
Session: ePoster Display
856P - A comparison of the burden of leukemia amongst European Union 15+ countries, 1990-2019
Presenter: Chinmay Jani
Session: ePoster Display
867P - A phase I trial of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma
Presenter: Ari Rosenberg
Session: ePoster Display
869P - Nivolumab (Nivo) and ipilimumab (Ipi) combined with radiotherapy (RT) in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN): Updated results of a pilot study
Presenter: Jennifer Johnson
Session: ePoster Display